Home Healthcare Biotechnology Cell and Gene Therapy Market

Cell and Gene Therapy Market Size, Share & Trends Analysis Report By Type (Cell Therapy, CAR-T Cell Therapy, CAR-NK, B-Cell, Others, Viral, Non-viral), By Application (Oncology, Dermatology, Musculoskeletal, Immunology, Neurology, Others), By Manufacturer (Biopharmaceutical & Biotechnology Companies, Pharmaceutical Companies, CDMOs/CMOs, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: March 16, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Cell and Gene Therapy Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Cell Therapy
    2. CAR-T Cell Therapy
      1. Autologous CAR-T
      2. Allogeneic CAR-T
    3. CAR-NK
    4. B-Cell
    5. Others
      1. Gene Therapy
    6. Viral
      1. AAV
      2. Lentiviral vectors
      3. Others
    7. Non-viral
  2. Cell and Gene Therapy Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. Dermatology
    3. Musculoskeletal
    4. Immunology
    5. Neurology
    6. Others
  3. Cell and Gene Therapy Market, By Manufacturer 2022-2034 (USD MILLION/ Units)
    1. Biopharmaceutical & Biotechnology Companies
    2. Pharmaceutical Companies
    3. CDMOs/CMOs
    4. Others
  4. Regional Cell and Gene Therapy Market
    1. North America
      1. North America Cell and Gene Therapy Market By Type 2022-2034 (USD MILLION/ Units)
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
      2. North America Cell and Gene Therapy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Dermatology
        3. Musculoskeletal
        4. Immunology
        5. Neurology
        6. Others
      3. North America Cell and Gene Therapy Market By Manufacturer 2022-2034 (USD MILLION/ Units)
        1. Biopharmaceutical & Biotechnology Companies
        2. Pharmaceutical Companies
        3. CDMOs/CMOs
        4. Others
      4. U.S.
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      5. Canada
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
    2. Europe
      1. Europe Cell and Gene Therapy Market By Type 2022-2034 (USD MILLION/ Units)
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
      2. Europe Cell and Gene Therapy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Dermatology
        3. Musculoskeletal
        4. Immunology
        5. Neurology
        6. Others
      3. Europe Cell and Gene Therapy Market By Manufacturer 2022-2034 (USD MILLION/ Units)
        1. Biopharmaceutical & Biotechnology Companies
        2. Pharmaceutical Companies
        3. CDMOs/CMOs
        4. Others
      4. U.K.
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      5. Germany
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      6. France
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      7. Spain
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      8. Italy
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      9. Russia
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      10. Nordic
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      11. Benelux
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      12. Rest of Europe
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
    3. APAC
      1. APAC Cell and Gene Therapy Market By Type 2022-2034 (USD MILLION/ Units)
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
      2. APAC Cell and Gene Therapy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Dermatology
        3. Musculoskeletal
        4. Immunology
        5. Neurology
        6. Others
      3. APAC Cell and Gene Therapy Market By Manufacturer 2022-2034 (USD MILLION/ Units)
        1. Biopharmaceutical & Biotechnology Companies
        2. Pharmaceutical Companies
        3. CDMOs/CMOs
        4. Others
      4. China
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      5. Korea
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      6. Japan
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      7. India
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      8. Australia
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      9. Taiwan
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      10. South East Asia
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      11. Rest of Asia-Pacific
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
    4. Middle East and Africa
      1. Middle East and Africa Cell and Gene Therapy Market By Type 2022-2034 (USD MILLION/ Units)
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
      2. Middle East and Africa Cell and Gene Therapy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Dermatology
        3. Musculoskeletal
        4. Immunology
        5. Neurology
        6. Others
      3. Middle East and Africa Cell and Gene Therapy Market By Manufacturer 2022-2034 (USD MILLION/ Units)
        1. Biopharmaceutical & Biotechnology Companies
        2. Pharmaceutical Companies
        3. CDMOs/CMOs
        4. Others
      4. UAE
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      5. Turkey
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      6. Saudi Arabia
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      7. South Africa
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      8. Egypt
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      9. Nigeria
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      10. Rest of MEA
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
    5. LATAM
      1. LATAM Cell and Gene Therapy Market By Type 2022-2034 (USD MILLION/ Units)
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
      2. LATAM Cell and Gene Therapy Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Dermatology
        3. Musculoskeletal
        4. Immunology
        5. Neurology
        6. Others
      3. LATAM Cell and Gene Therapy Market By Manufacturer 2022-2034 (USD MILLION/ Units)
        1. Biopharmaceutical & Biotechnology Companies
        2. Pharmaceutical Companies
        3. CDMOs/CMOs
        4. Others
      4. Brazil
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      5. Mexico
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      6. Argentina
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      7. Chile
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      8. Colombia
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
      9. Rest of LATAM
        1. Cell Therapy
        2. CAR-T Cell Therapy
          1. Autologous CAR-T
          2. Allogeneic CAR-T
        3. CAR-NK
        4. B-Cell
        5. Others
          1. Gene Therapy
        6. Viral
          1. AAV
          2. Lentiviral vectors
          3. Others
        7. Non-viral
        8. Oncology
        9. Dermatology
        10. Musculoskeletal
        11. Immunology
        12. Neurology
        13. Others
        14. Biopharmaceutical & Biotechnology Companies
        15. Pharmaceutical Companies
        16. CDMOs/CMOs
        17. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.